Concert Pharmaceuticals (NASDAQ:CNCE) released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.85) by $0.13, Fidelity Earnings reports. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.35 million. Concert Pharmaceuticals had a negative return on equity of 55.06% and a negative net margin of 7,291.37%.
CNCE traded up $0.25 during midday trading on Monday, hitting $7.21. 6,332 shares of the company were exchanged, compared to its average volume of 169,551. The firm has a market capitalization of $159.97 million, a P/E ratio of -3.02 and a beta of 0.88. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.14. The firm’s 50 day moving average price is $6.35 and its 200-day moving average price is $9.56. Concert Pharmaceuticals has a 1-year low of $5.36 and a 1-year high of $17.83.
A number of equities analysts have commented on the company. BidaskClub lowered Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, September 28th. HC Wainwright lowered their price objective on Concert Pharmaceuticals from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Janney Montgomery Scott restated a “buy” rating and set a $10.00 price objective (down previously from $13.00) on shares of Concert Pharmaceuticals in a research note on Monday, September 30th. Zacks Investment Research lowered Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, November 18th. Finally, ValuEngine lowered Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. Concert Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $15.22.
In other Concert Pharmaceuticals news, Director Heek Christi Van acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, October 8th. The shares were bought at an average cost of $5.90 per share, with a total value of $29,500.00. Following the purchase, the director now directly owns 5,000 shares of the company’s stock, valued at $29,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.00% of the stock is owned by insiders.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
See Also: Hedge Funds – Risk or Reward?